Kalaris Therapeutics Inc (KLRS)
Automate Your Wheel Strategy on KLRS
With Tiblio's Option Bot, you can configure your own wheel strategy including KLRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KLRS
- Rev/Share 0.0
- Book/Share 2.2386
- PB 4.4939
- Debt/Equity 0.0369
- CurrentRatio 12.8908
- ROIC -0.727
- MktCap 188146325.0
- FreeCF/Share -2.0409
- PFCF -4.9293
- PE -3.6385
- Debt/Assets 0.019
- DivYield 0
- ROE -0.76
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KLRS | Chardan Capital Markets | -- | Buy | -- | $19 | Dec. 23, 2025 |
| Initiation | KLRS | Citizens JMP | -- | Mkt Outperform | -- | $20 | Nov. 3, 2025 |
| Initiation | KLRS | Raymond James | -- | Strong Buy | -- | $23 | Sept. 3, 2025 |
| Resumed | KLRS | Piper Sandler | -- | Neutral | -- | $3 | July 23, 2025 |
| Initiation | KLRS | Leerink Partners | -- | Outperform | -- | $20 | May 7, 2025 |
| Initiation | KLRS | William Blair | -- | Outperform | -- | -- | April 8, 2025 |
News
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts
Published: December 19, 2025 by: Seeking Alpha
Sentiment: Positive
Kalaris Therapeutics offers a differentiated approach to neovascular AMD with its lead candidate TH103, leveraging unique molecular engineering for improved efficacy and durability. KLRS's Phase 1a data showed a clinically significant 10-letter visual acuity gain and promising durability, with 31% of patients needing no rescue injection for six months. With $77M in cash and a quarterly burn of ~$12M, KLRS is funded through 2027, enabling execution through the critical Phase 1b/2 data readout expected in H2 2026.
Read More
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth
Published: December 18, 2025 by: Seeking Alpha
Sentiment: Positive
Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash position to fund TH103 clinical development. KLRS reported improved Q3 '25 results, with a net loss of $11.9M and $77M in cash, supporting operations through 2027. TH103, KLRS's lead asset, showed rapid efficacy and strong safety in Phase 1a, with further Phase 1b/2 data expected in H2 '26.
Read More
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Published: September 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103
Read More
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Kalaris Therapeutics Inc. (KLRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of AlloVir, Inc. securities (NASDAQ: KLRS):
Read More
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference.
Read More
Kalaris to Participate at Stifel Ophthalmology Forum
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum.
Read More
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth
Read More
About Kalaris Therapeutics Inc (KLRS)
- IPO Date 2020-07-30
- Website https://kalaristx.com
- Industry Biotechnology
- CEO Andrew Oxtoby
- Employees 14